Compare IDEXX Laboratories, Inc. (IDXX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Microsoft — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Microsoft trades at $491.62 (market cap $3.74T). The key difference: Microsoft is far larger — about 80.9× IDEXX Laboratories, Inc.'s market cap, and Microsoft pays a 0.72% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MSFT | |
|---|---|---|
Market Cap | $46.22B | $3.74T |
Sector | Health | Technology |
52-Week High | $766.68 | $542.07 |
52-Week Low | $526.44 | $352.83 |
Enterprise Value | $47.12B | $3.72T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Microsoft (MSFT) trades at $493.21, down 2.54% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 estimate. Revenue grew to $281.72 billion in 2025, supported by a net income margin of 40.31% and robust cash flow from operations of $136.16 billion. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a $555 consensus price target, implying over 12% upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 28.07, and macroeconomic volatility. The stock's fundamentals and institutional support suggest long-term growth potential, but investors should monitor execution on AI investments and spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
